A functional in vitro assay for screening inhibitors of STAT5B phosphorylation

[1]  Jisung Park,et al.  High‐throughput thermofluor‐based assays for inhibitor screening of STAT SH2 domains , 2017, Journal of pharmaceutical and biomedical analysis.

[2]  J. Matysik,et al.  Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b , 2017, Scientific Reports.

[3]  P. Lai,et al.  CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence , 2016, Oncogene.

[4]  M. Geletu,et al.  Strategies for over-expression and purification of recombinant full length STAT5B in Escherichia coli. , 2017, Protein expression and purification.

[5]  P. Lai,et al.  Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)‐Resistant CML Lines While Circumventing Pharmacokinetic Liabilities , 2016, ChemMedChem.

[6]  V. Kanelis,et al.  Phosphorylation-dependent Changes in Nucleotide Binding, Conformation, and Dynamics of the First Nucleotide Binding Domain (NBD1) of the Sulfonylurea Receptor 2B (SUR2B)* , 2015, The Journal of Biological Chemistry.

[7]  T. Berg,et al.  Nanomolar Inhibitors of the Transcription Factor STAT5b with High Selectivity over STAT5a , 2015, Angewandte Chemie.

[8]  V. Kanelis,et al.  Successful development and use of a thermodynamic stability screen for optimizing the yield of nucleotide binding domains. , 2014, Protein expression and purification.

[9]  David E. Muench,et al.  Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein , 2014, ACS medicinal chemistry letters.

[10]  B. Garcia,et al.  Stable Isotope Labeling of Phosphoproteins for Large-scale Phosphorylation Rate Determination* , 2014, Molecular & Cellular Proteomics.

[11]  A. Maitra,et al.  APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1–STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival , 2012, PloS one.

[12]  J. Glickman.  Assay Development for Protein Kinase Enzymes , 2012 .

[13]  G. Superti-Furga,et al.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. , 2012, Nature chemical biology.

[14]  P. Hodder,et al.  Modulators of STAT Transcription Factors for the Targeted Therapy of Cancer (STAT3 Inhibitors) , 2011 .

[15]  Yu Xue,et al.  GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. , 2011, Protein engineering, design & selection : PEDS.

[16]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[17]  T. Berg,et al.  A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. , 2004, Analytical biochemistry.

[18]  C. Austin,et al.  Assay Development for Protein Kinase Enzymes -- Assay Guidance Manual , 2004 .

[19]  Wayne F. Patton,et al.  Global quantitative phosphoprotein analysis using Multiplexed Proteomics technology , 2003, Proteomics.

[20]  Matthew B. Wilson,et al.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells , 2002, The EMBO journal.

[21]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.